PTC Therapeutics Management

Management criteria checks 3/4

PTC Therapeutics' CEO ist Matt Klein , ernannt in Mar 2023, hat eine Amtszeit von 1.08 Jahren. Die jährliche Gesamtvergütung beträgt $5.01M , bestehend aus 11.9% Gehalt und 88.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.057% der Aktien des Unternehmens, im Wert von $1.26M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.2 Jahre bzw. 8.8 Jahre.

Key information

Matt Klein

Chief executive officer

US$5.0m

Total compensation

CEO salary percentage	11.9%
CEO tenure	1.1yrs
CEO ownership	0.06%
Management average tenure	7.2yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27

PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

Apr 11

Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?

Feb 09

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate

Dec 27

CEO Compensation Analysis

How has Matt Klein's remuneration changed compared to PTC Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$627m
Sep 30 2023	n/a	n/a	-US$642m
Jun 30 2023	n/a	n/a	-US$618m
Mar 31 2023	n/a	n/a	-US$571m
Dec 31 2022	US$5m	US$598k	-US$559m

Vergütung im Vergleich zum Markt: MattDie Gesamtvergütung ($USD5.01M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.11M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Matt mit der Unternehmensleistung zu vergleichen.

CEO

Matt Klein (51 yo)

1.1yrs

Tenure

US$5,009,299

Compensation

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Matthew Klein	CEO & Director	1.1yrs	US$5.01m	0.057% $ 1.2m
Stuart Peltz	Co-Founder	26.3yrs	US$7.16m	0.097% $ 2.1m
Allan Jacobson	Co-Founder	26.3yrs	US$553.96k	0.016% $ 353.1k
Neil Almstead	Chief Technical Operations Officer	5.3yrs	US$2.67m	0.054% $ 1.2m
Eric Pauwels	Chief Business Officer	9yrs	US$2.99m	0.022% $ 492.6k
Pierre Gravier	Chief Financial Officer	less than a year	no data	0.010% $ 220.1k
Christine Utter	Senior VP	4.8yrs	US$1.70m	0.022% $ 487.5k
Alex Kane	Investor Relations Officer	no data	no data	no data
Mark Boulding	Executive VP & Chief Legal Officer	12.1yrs	US$4.29m	0.064% $ 1.4m
Jane Baj	Vice President of Corporate Communications	no data	no data	no data
Hege Sollie-Zetlmayer	Senior Vice President of Human Resources	3.5yrs	no data	no data
Murad Husain	Senior Vice President of Global Regulatory Affairs	9.3yrs	no data	no data

7.2yrs

Average Tenure

59yo

Average Age

Erfahrenes Management: Das Managementteam von PTCT ist erfahren und erfahren (durchschnittliche Amtszeit: 6.8 Jahre).

Board Members

Name	Position	Tenure	Compensation	Ownership
Matthew Klein	CEO & Director	1.1yrs	US$5.01m	0.057% $ 1.2m
Stuart Peltz	Co-Founder	1.1yrs	US$7.16m	0.097% $ 2.1m
Allan Jacobson	Co-Founder	26.3yrs	US$553.96k	0.016% $ 353.1k
Michael Schmertzler	Independent Chairman of the Board	22.7yrs	US$908.42k	1.96% $ 42.9m
David Southwell	Independent Director	18.3yrs	US$488.46k	0.0085% $ 185.7k
Eric Jacobsen	Member of the Scientific Advisory Board	no data	no data	no data
Emma Reeve	Independent Director	5.3yrs	US$491.46k	0.0094% $ 205.9k
Joseph Puglisi	Member of Scientific Advisory Board	20.4yrs	no data	no data
Glenn Steele	Independent Director	8.8yrs	US$468.96k	0.0085% $ 185.7k
Marvin Wickens	Member of Scientific Advisory Board	no data	no data	no data
Robert Schneider	Member of Scientific Advisory Board	no data	no data	no data
Stephanie Okey	Independent Director	5.3yrs	US$463.96k	0.0077% $ 167.8k

8.8yrs

Average Tenure

63yo

Average Age

Erfahrener Vorstand: PTCTDie Vorstandsmitglieder gelten als erfahren (8.8 Jahre durchschnittliche Amtszeit).

PTC Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

Recent updates

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Price target decreased to US$51.46

Insufficient new directors

Price target decreased to US$52.31

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.

Executive VP & Chief Legal Officer exercised options and sold US$167k worth of stock

PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Executive VP & Chief Legal Officer notifies of intention to sell stock

Price target increased to US$54.64

Insider recently sold US$119k worth of stock

Consensus forecasts updated

PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2022

PTC Therapeutics, Inc. Announces Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors

PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind